Germinal mosaicism for a deletion of the FMR1 gene leading to fragile X syndrome

Eur J Med Genet. 2016 Sep;59(9):459-62. doi: 10.1016/j.ejmg.2016.08.009. Epub 2016 Aug 18.

Abstract

Aberrant CGG trinucleotide amplification within the FMR1 gene, which spans approximately 38 Kb of genomic DNA is almost always what leads to fragile X syndrome (FXS). However, deletions of part or the entire FMR1 gene can also cause FXS. Both CGG amplification-induced silencing and deletions result in the absence of the FMR1 gene product, FMRP. Here, we report a rare case of germinal mosaicism of a deletion encompassing approximately 300 Kb of DNA, which by removing the entire FMR1 gene led to FXS. The male proband, carrying the deletion, presented in clinic with the typical features of FXS. His mother was analyzed by FISH on metaphase chromosomes with cosmid probe c22.3 spanning the FMR1 locus, and she was found not to carry the deletion on 30 analyzed cells from peripheral blood lymphocytes. Prenatal examination of the mother's third pregnancy showed that the male fetus also had the same deletion as the proband. Following this prenatal diagnosis, FISH analysis in the mother was expanded to 400 metaphases from peripheral lymphocytes, and a heterozygous FMR1 deletion was found in three. Although this result could be considered questionable from a diagnostic point of view, it indicates that the deletion is in the ovary's germinal cells.

Keywords: FMR1 gene; Fragile X; Germinal mosaicism; Large deletions.

Publication types

  • Case Reports

MeSH terms

  • Child
  • Female
  • Fragile X Mental Retardation Protein / genetics*
  • Fragile X Syndrome / drug therapy
  • Fragile X Syndrome / genetics*
  • Gene Deletion*
  • Genetic Counseling
  • Humans
  • In Situ Hybridization, Fluorescence
  • Infant, Newborn
  • Male
  • Mosaicism*
  • Pregnancy
  • Prenatal Diagnosis
  • Sertraline / therapeutic use

Substances

  • FMR1 protein, human
  • Fragile X Mental Retardation Protein
  • Sertraline